Retatrutide: The Next GLP-1 Just Changed the Game (Phase 3 Results Are In)

Hinzugefügt: 2026-05-23

[00:00:00]Most people think weight loss surgery is the ceiling for severe obesity, but the latest trials from Eli Liy on retatrite completely blow that out of the water.

[00:00:09]In this video, I'm going to talk about what they found and what this means for the future of GLP-1 drugs. The first I want to talk about what retatride is and why it is different. If you don't know me, my name is Lane. I like to help people in their 40s and 50s and beyond get their lives back by resetting their physiques. I lost 55 pounds after 40 years old using Tzepide, weightlifting, and testosterone. And the three of those things together completely changed my life. Right now, I'm in Santa Monica on a trip and I'm in a hotel room. So, my setup is a little bit different today.

[00:00:41]But I wanted to address this because this is a huge huge deal. This is not just a GLP-1 drug. It's a triple agonist. So, simaglutide was the first one to come out. That's Ozimpic and WGO.

[00:00:54]That's a GLP-1. It's basically just that compound. Then we had tzepide which is what I use and love. It's GLP-1, GIP.

[00:01:02]It's a dual agonist. Retatrutide is GLP-1, GIP, and glucagon. And it's that third agonist that's doing a lot of heavy lifting. Before we go any further, I want to mention this is not FDA approved. It's still in clinical trials with Eli Liy. They expect that pretty soon, like in the next six months to a year, it should get its FDA approval and come out as a full-blown obesity drug.

[00:01:25]Now, lots of people already access reatride. But I want to stress that when you do that, you're using a research product and so I don't recommend it. In fact, I don't recommend anything because I'm not a doctor and this is not medical advice. So ask your doctor. By the way, if you don't have a doctor, lemmd.comreset, is my link that I use to get tzepide, which is how I lost my 55 pounds. What they do is they pair you with a doctor who's licensed to practice in your state. You fill out a quick intake form, they pair you with that doctor, and then you get your drug within two days, shipped to your door. No fillers, no preservatives, made in the United States, 503A pharmacy. It's an amazing company. That link is my link. So, when you use it, I do get a small commission, but at no additional cost to you. So let's talk though about retatrite. It's the first triple agonist to reach phase three trials. So we we're we're well into the trials. We have so much data.

[00:02:20]They're still investigating it. Again, it's not FDA approved. I want to mention that once again. So let's talk about the numbers that we found that matter. At 12 milligrams over 80 weeks, an average loss of 70 pounds. Okay, this is 28% of body weight. 45% of participants hit 30% uh of plus weight loss, a threshold historically associated with beriatric surgery. So this is where this changes everything. Semaglutide got us to about 15%. Tzepide got us to 22% of body weight. Red ratutide is getting us to 28%. The reason why this is this is such a big deal is we've never seen these kind of numbers outside of surgery.

[00:03:05]There's just never been a case where people have been able to use in this case like an injection and get these kinds of results without having a very invasive and sometimes dangerous gastro beriatric surgery. So this is huge. When you extend it out to 104 weeks, participants continued losing reaching an average of 85 pounds lost. All right, that's 30% of body weight. Even at the lowest four milligram dose, just one escalation step, people lost an average of 47.2 pounds, that's 19% and at the lower dose, they have a lower side effect dropout rate than the placebo. So the the the thing that keeps happening with the reatride trials is most of the kind of like wow that comes from it is at pretty high doses like 12 milligrams.

[00:03:56]That's a pretty high dose to give you an an idea of how this works. And reatride is different than tzepide. So it's not apples to apples. But I just want to mention on tzepatide I started out at 2.5. I was on 2.5 for the first four weeks. I lost six pounds in four weeks.

[00:04:11]It started to lose its efficacy. I started to realize it didn't really have the effect that I I had at first. So my doctor moved me from 2.5 to five. I stayed at five for the rest of the time that I was on uh that I was losing the weight. Right now, what I do is I actually get a 7.5 prescription, but I cut it in half. So, I'm actually getting 3.75. So, I'm somewhere between the starting dose of of 2.5 and five. I'm at 3.75. And that seems to be a pretty good maintenance dose for me. And I'm going to continue lowering that as as my body adjusts to this new weight. By the way, if you want to know how it works in terms of your body's desire to get back to your body's set weight, check out this video, which I'll link at the end of of our video here, because it explains this so well about how your body effectively has a weight that it wants to be. If you've been fat for a long time, like I was, I was 240 lbs for a long time, and my body wants to get back to that. So the longer I can hold at 180, 182, 185, the more normal that becomes and the less my body fights me to get back. Which is why a lot of people have asked me, "When are you going off of Tzepite?" Right now I have no plans to because I want to hold my weight for at least the next two to three years to keep that going. So again, at a really high dose of 12 milligrams, there are some side effects that you can avoid at lower doses. Not everybody needs to lose 28 or 30% of their body weight. Not everybody needs to lose 70 pounds and not everybody needs to lose it that fast. I think you can still go with a lower dose and get some results. How does this stack up against other weight loss drugs? So semiglutide which is oipic or wobbi has a 15% body weight loss. Zepbound or Tzepide GLP-1 GIP has a 22% body weight loss and then Red True Tide has a 28% and still going at two years. So what I mean by that is right now it's 28% but every time they come out with a new trial these numbers actually keep getting better. So there's no direct head-to-head trial yet between ratutide and tzepide. We're kind of waiting for that. That would be really cool to see a head-to-head trial. But we can compare the clinical trials of simaglutide and tresepide to the clinical trials of bittatrutide. And then we have actual data like not just clinical trials but clinical data 20 years on simaglutide.

[00:06:38]People don't realize this. I've had a lot of people comment and say you don't know the long-term side effects of these. You know you're putting yourself at risk. These drugs have been used to treat type 2 diabetes since 2005.

[00:06:49]Simaglutide has been used to treat type 2 diabetes for 21 years. So we have 21 years not just of clinical trials but actual practice clinical data. It is not a mystery what these drugs do or what their side effects are. So let's talk about beyond weight loss. What are we seeing with reatrite? This is where it gets really exciting. So we see improvements in waist circumference.

[00:07:12]This is a big deal. So body mass index is something that I talked about in one of my recent videos and how it sucks.

[00:07:18]Body mass index sucks. It's it just doesn't it's not accurate to how we actually live. Because for me at 182 pounds at 5'11 I have a body mass index of 25 which is not even a normal weight yet. I'm still technically overweight.

[00:07:35]However, I'm not I have 14% body fat.

[00:07:38]Like what? But because I lift weights and I have these massive muscles, um it it it throws off the BMI. It's just not made for anybody who actually does resistance training. And if you're not doing resistance training while you're on a GLP-1, you're just putting you're just making life hard on yourself. So, this is why I am a huge proponent of making sure that you're doing resistance training and you are uh you're you're tackling your physique in that way. But waist circumference is a better measure.

[00:08:09]In fact, I I heard the other day that they're kind of moving away from BMI to BRI. So instead of body mass index, the real measure is body roundness index. So how how much around your waist is there compared to relative to other parts of your body. So if you can get your waist circumference down, that means you get rid of visceral fat and around your abdomen and you're just healthier. So for me in my journey, I started at 46 in and I got down to 33 in around the waist and my jean size went from 34 to 31. So triglycerides, blood pressure, cholesterol, and inflammation markers all improve on retoide. There's a separate trial data that shows significant reductions in knee osteoarthritis pain, especially in women. This is very exciting. It just zaps it. It zaps the pain from u knee osteoarthritis.

[00:09:01]There's still data coming in in 2026, but uh covering diabetes and cardiovascular uh disease patients, but we're we're seeing some really good things out of there. Now let's talk about the side effects of ratutide because they are there. The first one is that the GI side effects are real and higher than tzepide. So with simaglutide the GI effects were pretty pretty big.

[00:09:23]It lowered with tzepide. That's one of the reasons why I love tzepide GLP1 gip because some people get on simaglutide and they they they're just nauseous right away. This is how it was for my wife. She started out on a compounded uh simaglutide. It did not do well for her.

[00:09:39]It wasn't LEMD. So, I'm wondering if LEMD would be better, but where she got it, it just made her sick. We put her on uh Tzepide, GLP1 GIP, and the the nausea went away. So, it corrected that. But reatride kind of goes back, especially at higher doses where people are experiencing more GI side effects. Vomiting was reported in up to 25% of patients of participants at the higher doses versus 4.8% for placebo. So it's is still investigational. There's no FDA approval at this time. And um don't conflate this with what's available today. So what's available today uh with the FDA is simaglutide and tzepide. Retat trueide is still in its trial phase which means it could we could continue to see different things. It could not get approval although all of us expect it to and again hundreds of thousands if not millions of people are already on it through compoundingies and research products. This is though what I think is the future of GLP-1 therapy and it's closer than most people realize. So this is not a fringe thing. This is this is where it's going. That glucagon receptor that third that third agonist that hits a glucagon receptor has a way of directly targeting and mobilizing fat especially in the liver. So what we're seeing and this was the the other trial that was really big on this. It reduces fatty liver disease. It it was I think it was 89% reduction in fatty liver disease. That's incredible. There's nothing that does this. Um Tzepide comes pretty close. Tzepide goes does a really good job. In fact, I had a comment from someone who has non-alcoholic fatty liver disease and was close to being put on the on the transplant the the transplant transplant list for liver.

[00:11:23]But she started takingide and all of that fatty liver went away. So it's not just reatride that does it. Tzepide does it as well. It's just that what renatide does is it targets fat in a way that trespatide doesn't. Tzepite does because the GIP agonist does, but reatrite that glucagon agonist really hits and mobilizes fat. Which is why most people who are on reaction as suppressed as it is on tzepatide, but because the glucagon is target directly targeting fat, it's actually reducing their fat anyway. So they're losing weight and they're able to eat more.

[00:12:06]This is this is why so many people so many gym rats and bodybuilders love Reetta because it allows them to eat more. So they're getting more protein, they're preserving muscle, but they're still losing fat. So it's kind of like a miracle for people who are interested in preserving as much muscle as possible and reducing as much fat as possible. If you're already on turppetite and it's working, stay the course. Okay, this is what's next. Eventually be FDA approved.

[00:12:35]Eventually, uh, places like, uh, lemmd.comreset will have it, but right now it's not.

[00:12:41]And so, my suggestion is always talk to your doctor. And again, if you don't have a doctor, lemmd.com/reset or if your doctor's giving you problems about this or if your insurance doesn't cover you, go to lemd.com/reset and you'll find you'll find a path that works. But if you're already on Tzepide and it's working, there's no reason to stop yet. I am probably going to experiment with this when it is FDA approved because I'm so intrigued by some of the things that it does and I want to see how it feels so I can report back to you. But stay the course and let me know because I know if you're watching this half of you are already on rea. Okay? So tell me what it's like if you're on reatite, especially if you were on tzepide but now you're on rea.

[00:13:22]What are the differences that you're seeing? How is it working for you? I'd love to know. Let me know and uh we'll talk about it more in the comments. And if you haven't subscribed yet, subscribe. I just hit a thousand and I'm so pumped. Like last night I was going to bed, it was $9.99. I woke up this morning, it was,31. So I was like, "Oh my gosh." So subscribe because I just I love it when you say, "Yes, I like this.

[00:13:43]I want more." And that tells me and it tells YouTube that you're liking this.

[00:13:46]So, I'll see you in the next